...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Helicobacter pylori Diagnostics and Treatment: Could a Lack of Universal Consensus Be the Best Consensus?
【24h】

Helicobacter pylori Diagnostics and Treatment: Could a Lack of Universal Consensus Be the Best Consensus?

机译:幽门螺杆菌的诊断和治疗:缺乏普遍共识可以成为最佳共识吗?

获取原文
           

摘要

Helicobacter pylori testing and treatment has become a subject of intense debate and confusion worldwide in recent years, for both laboratory scientists and clinicians. The gastric pathogen H. pylori is believed to infect up to half of the world's population disproportionately, yet it remains a challenging diagnosis for many physicians worldwide. New testing mechanisms have been introduced, but no single universal approach for testing and treating H. pylori has been established to date. In effect, no population on earth has been spared from these chronic infections, but regional differences in prevalence and associated disease severity do exist. Not unexpectedly, there also exist regional approaches in the diagnosis, treatment, and management of these patients. This Q&A borrows the experience of 3 international experts in the field of H. pylori to reflect on the current status of H. pylori management and challenges on 3 separate continents, specifically Australia, Europe, and North America.Several different guidelines exist for the diagnosis/treatment of H. pylori infections. What controversy or challenges do you perceive with current guidelines? Barry Marshall: Guidelines for the treatment of H. pylori infections are aimed toward achieving a cure rate of at least 85%. In the past 10 years, because of gradually increasing resistance to macrolides, the very successful and popular combination treatment using a proton pump inhibitor (PPI),6 clarithromycin, and amoxicillin has declined in effectiveness from greater than an 85% cure rate originally, to the region of 70%–80% in some areas where long-acting macrolides have been used for 10 or more years. This has created research interest in the evaluation of newer and more intensive therapies, often with extra antibiotics added to hopefully eradicate the H. pylori without the emergence of resistant isolates. Over the years, shorter and more-intensive treatments for H. pylori infection have been tried, and these are …
机译:近年来,对于实验室科学家和临床医生来说,幽门螺杆菌的检测和治疗已成为全球争论和困惑的主题。据信胃病原体幽门螺杆菌不成比例地感染了全世界一半的人口,但是对于全世界的许多医生来说,它仍然是具有挑战性的诊断。引入了新的测试机制,但迄今为止尚未建立用于测试和治疗幽门螺杆菌的单一通用方法。实际上,地球上没有任何人能够幸免于这些慢性感染,但是确实存在患病率和相关疾病严重程度的区域差异。不出所料,在这些患者的诊断,治疗和管理中也存在区域性方法。此次问答集借鉴了3位幽门螺杆菌领域的国际专家的经验,以反思幽门螺杆菌的管理现状和在3个独立大洲(特别是澳大利亚,欧洲和北美)的挑战。存在几种不同的诊断指南/幽门螺杆菌感染的治疗。您对当前指南有何争议或挑战? Barry Marshall:幽门螺杆菌感染的治疗指南旨在达到至少85%的治愈率。在过去的十年中,由于对大环内酯类药物的耐药性逐渐提高,使用质子泵抑制剂(PPI),6克拉霉素和阿莫西林的非常成功且流行的联合治疗的疗效已从最初的大于85%下降到了在长效大环内酯类药物已使用10年或更长时间的某些地区,这一比例为70%–80%。这引起了人们对评估更新和更深入疗法的研究兴趣,通常会添加额外的抗生素以根除幽门螺杆菌而不会出现耐药分离株。多年来,已经尝试了更短,更密集的幽门螺杆菌感染治疗方法,这些是……

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号